These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31653146)

  • 1. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
    Abe H; Takei K; Uematsu T; Tokura Y; Suzuki I; Sakamoto K; Nishihara D; Yamaguchi Y; Mizuno T; Nukui A; Kobayashi M; Kamai T
    Int J Clin Oncol; 2018 Apr; 23(2):338-346. PubMed ID: 29098519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
    Yumioka T; Honda M; Nishikawa R; Teraoka S; Kimura Y; Iwamoto H; Morizane S; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jan; 25(1):158-164. PubMed ID: 31520176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma.
    Taguchi S; Akamatsu N; Nakagawa T; Gonoi W; Kanatani A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Homma Y
    Clin Genitourin Cancer; 2016 Jun; 14(3):237-43. PubMed ID: 26337653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy.
    Gao Z; Pang Y; Qin X; Li G; Wang Z; Zhang L; Wang J; Qi N; Li H
    Int J Clin Oncol; 2024 May; 29(5):592-601. PubMed ID: 38514497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
    Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
    Naiki T; Kawai N; Hashimoto Y; Okamura T; Ando R; Yasui T; Okada A; Etani T; Tozawa K; Kohri K
    Int J Clin Oncol; 2014; 19(3):516-22. PubMed ID: 23749066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
    Takeyama Y; Kato M; Nishihara C; Yamasaki T; Iguchi T; Tamada S; Kuratsukuri K; Nakatani T
    Int J Clin Oncol; 2018 Oct; 23(5):944-950. PubMed ID: 29785621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
    Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
    Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
    Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the skeletal muscle index and an inflammation biomarker in patients with breast cancer who underwent postoperative adjuvant radiotherapy.
    Hua X; Deng JP; Long ZQ; Zhang WW; Huang X; Wen W; Guo L; He ZY; Lin HX
    Curr Probl Cancer; 2020 Apr; 44(2):100513. PubMed ID: 31732239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
    Tsang ES; Forbes C; Chi KN; Eigl BJ; Parimi S
    Curr Oncol; 2019 Apr; 26(2):e260-e265. PubMed ID: 31043835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.